Suppr超能文献

达可替尼用于肺癌治疗:来自过去时代的“失落一代”表皮生长因子受体酪氨酸激酶抑制剂?

Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?

作者信息

Ou Sai-Hong Ignatius, Soo Ross A

机构信息

Chao Family Comprehensive Cancer Center, Division of Hematology/Oncology, Department of Medicine, University of California, Irvine School of Medicine, Orange, CA, USA.

National University Health System and Cancer Science Institute of Singapore, Singapore.

出版信息

Drug Des Devel Ther. 2015 Oct 15;9:5641-53. doi: 10.2147/DDDT.S52787. eCollection 2015.

Abstract

EGFR tyrosine-kinase inhibitors (TKIs) have now been firmly established as the first-line treatment for non-small-cell lung cancer (NSCLC) patients harboring activating EGFR mutations, based on seven prospective randomized Phase III trials. However, despite significantly improved overall response rate and improved median progression-free survival when compared to platinum-doublet chemotherapy, EGFR-mutant NSCLC patients treated with EGFR TKIs invariably progress due to the emergence of acquired resistances, with the gatekeeper T790M mutation accounting for up to 60% of the resistance mechanisms. Second-generation irreversible EGFR TKIs were developed in part to inhibit the T790M mutation, in addition to the common activating EGFR mutations. Dacomitinib is one such second-generation EGFR TKI designed to inhibit both the wild-type (WT) EGFR and EGFR T790M. Afatinib is another second-generation EGR TKI that has been now been approved for the first-line treatment of EGFR-mutant NSCLC patients, while dacomitinib continues to undergo clinical evaluation. We will review the clinical development of dacomitinib from Phase I to Phase III trials, including the two recently published negative large-scale randomized Phase III trials (ARCHER 1009, NCIC-BR-26). Results from another large-scale randomized trial (ARCHER 1050) comparing dacomitinib to gefitinib as first-line treatment of advanced treatment-naïve EGFR-mutant NSCLC patients will soon be available and will serve as the lynchpin trial for the potential approval of dacomitinib in NSCLC. Meanwhile, third-generation EGFR TKIs (eg, CO-1686 [rociletinib], AZ9291, HM61713, EGF816, and ASP8273) that preferentially and potently inhibit EGFR T790M but not WT EGFR are in full-scale clinical development, and some of these EGFR TKIs have received "breakthrough" designation by the US Food and Drug Administration and will likely be approved in late 2015. Given the rapid development of third-generation EGFR TKIs and the approval of gefitinib, erlotinib, and afatinib as first-line treatment of EGFR-mutant NSCLC patients, the future role of dacomitinib in the treatment of NSCLC seems to be limited.

摘要

基于七项前瞻性随机III期试验,表皮生长因子受体酪氨酸激酶抑制剂(TKIs)现已被明确确立为治疗携带表皮生长因子受体(EGFR)激活突变的非小细胞肺癌(NSCLC)患者的一线治疗方案。然而,尽管与铂类双联化疗相比,总体缓解率显著提高,中位无进展生存期也有所改善,但接受EGFR TKIs治疗的EGFR突变NSCLC患者由于获得性耐药的出现最终都会病情进展,其中守门人T790M突变占耐药机制的比例高达60%。第二代不可逆EGFR TKIs的研发部分是为了抑制T790M突变,同时也能抑制常见的EGFR激活突变。达可替尼就是这样一种第二代EGFR TKI,旨在抑制野生型(WT)EGFR和EGFR T790M。阿法替尼是另一种第二代EGR TKI,现已被批准用于EGFR突变NSCLC患者的一线治疗,而达可替尼仍在进行临床评估。我们将回顾达可替尼从I期到III期试验的临床研发情况,包括最近公布的两项大规模随机III期阴性试验(ARCHER 1009、NCIC-BR-26)。另一项将达可替尼与吉非替尼作为初治晚期EGFR突变NSCLC患者一线治疗进行比较的大规模随机试验(ARCHER 1050)的结果即将公布,该试验将成为达可替尼在NSCLC中获得潜在批准的关键试验。与此同时,优先且强效抑制EGFR T790M而不抑制WT EGFR的第三代EGFR TKIs(如CO-1686[罗西替尼]、AZ9291、HM61713、EGF816和ASP8273)正在全面开展临床研发,其中一些EGFR TKIs已获得美国食品药品监督管理局的“突破性”认定,可能在2015年末获得批准。鉴于第三代EGFR TKIs的快速发展以及吉非替尼、厄洛替尼和阿法替尼被批准用于EGFR突变NSCLC患者的一线治疗,达可替尼在NSCLC治疗中的未来作用似乎有限。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44e2/4610796/de47925bbb39/dddt-9-5641Fig1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验